Table 3.
In-transit Melanoma Treatment Outcome Comparisons.
| Treatment | OR | CR | PFS | OS |
|---|---|---|---|---|
| Novel vaccines | ||||
| T-VEC | 26% | 16% | Median 18.9 months | |
| PV-10 | 51% | 26% | ||
| Regional therapies | ||||
| ILP | 81%–90% | 50%–82% | Median 6–26 months | Median 24–51 months |
| ILI | 43%–84% | 30%–44% | Median 31–53 months | |
| Systemic therapies | ||||
| BRAF | 48%–81% | 1%–6% | Median 5.3–6.9 months | Median 13.6 months |
| 55% (1 year) | ||||
| Ipilimumab | 11%–29% | 1.50% | Median 2.9 months | Median 10.1 months 47%–53% (1 year) |
| PD-1 | 26%–52% | Median 5.5 months 42.1% (1 year) | Median 8.2 months 69%–73% (1 year) | |
OR = Overall Response; CR = Complete Response; PFS = Progression-Free Survival; OS = Overall Survival.